Zoledronic acid hydrate

• CAT Number: I002170
• CAS Number: 165800-06-6
• Molecular Formula: C5H12N2O8P2
• Molecular Weight: 290.1
• Purity: ≥95%
• Target: PKC
• Solubility: water：7 mg/ml
• Storage: -20°C
• IUPAC Name: (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid;hydrate
• InChI: InChI=1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2
• InChIKey: FUXFIVRTGHOMSO-UHFFFAOYSA-N
• SMILES: C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O.O

Zoledronic acid hydrate (CAT: I0021706) is a bisphosphonate drug used for the treatment of bone diseases such as osteoporosis and bone metastases. It works by inhibiting the activity of osteoclasts, which are responsible for bone resorption. Zoledronic acid specifically targets the bone, where it is taken up by osteoclasts and inhibits their function, leading to a decrease in bone breakdown. This medication is typically administered intravenously and has a long duration of action, with a single dose providing therapeutic effects for several months. Zoledronic acid hydrate is an important therapeutic option in the management of various bone-related conditions.

Reference

[1]. Berenson, J.R., et al., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer, 2001. 91(7): p. 1191-200.
[2]. Bilston, L.E., et al., Zoledronic acid improves the mechanical properties of normal and healing bone. Clin Biomech (Bristol, Avon), 2002. 17(9-10): p. 716-8.
[3]. Zoledronic acid: new preparation. Just a me-too: no advance in hypercalcemia of malignancy. Prescrire Int, 2002. 11(61): p. 140-1.